Clinical Trials
8 trialsNCT05733715 2026-03-24
Neoadjuvant Pembrolizumab and Lenvatinib for Renal Cell Carcinoma
Abramson Cancer Center at Penn Medicine
Phase EARLY_PHASE1 Recruiting
NCT07356466 2026-01-21
FUGES032
Fujian Medical University
Phase EARLY_PHASE1 Enrolling by invitation
NCT05041153 2026-01-12
Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma
M.D. Anderson Cancer Center
Phase EARLY_PHASE1 Recruiting
NCT05188118 2024-11-06
Rapid Sequencing of Approved Therapies in Patients with Metastatic or Unresectable Clear Cell Renal Cell Carcinoma
Icahn School of Medicine at Mount Sinai
Phase EARLY_PHASE1 Recruiting
NCT06327269 2024-04-18
Innovative Diagnosis and Therapy in LDLT Patients With High-risk Hepatocellular Carcinoma
Chang Gung Memorial Hospital
Phase EARLY_PHASE1 Recruiting
NCT04974281 2022-08-18
PD-1 Antibody and Lenvatinib Plus TACE on Downstaging BCLC B/C HCC
Fudan University
Phase EARLY_PHASE1 Unknown
NCT05411757 2022-06-09
IBR900 Cell Injection Combined With Lenvatinib or Bevacizumab in the Treatment of Advanced Primary Liver Cancer
Shandong Public Health Clinical Center
Phase EARLY_PHASE1 Unknown
NCT05007587 2021-08-16
Lenvatinib Plus HAIC of Modified FOLFOX Regime vs Lenvatinib Plus HAIC of ROX Regime in Patients With Advanced HCC
Zhejiang Cancer Hospital
Phase EARLY_PHASE1 Unknown